|
US4812397A
(en)
|
1987-02-10 |
1989-03-14 |
The Regents Of The University Of California |
MAB-anti-DNA related to nephritis
|
|
WO1989007142A1
(en)
|
1988-02-05 |
1989-08-10 |
Morrison Sherie L |
Domain-modified constant region antibodies
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
AU707440B2
(en)
|
1994-03-29 |
1999-07-08 |
Celltech Therapeutics Limited |
Antibodies against E-selectin
|
|
JP2000507225A
(ja)
|
1996-03-08 |
2000-06-13 |
ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア |
ｍａｂ ３Ｅ１０ ならびにその突然変異体および／または機能性フラグメントを使用する送達システム
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
JP2007501021A
(ja)
|
2003-05-30 |
2007-01-25 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
遺伝子操作された定常領域を含む、抗体および融合タンパク質
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
ES2911034T3
(es)
|
2006-08-08 |
2022-05-17 |
Univ Bonn Rheinische Friedrich Wilhelms |
Estructura y uso de oligonucleótidos 5' fosfato
|
|
DK2176408T5
(en)
|
2008-01-31 |
2015-12-14 |
Curevac Gmbh |
Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
|
|
WO2009141146A1
(en)
|
2008-05-21 |
2009-11-26 |
Gunther Hartmann |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
US20110184045A1
(en)
|
2008-06-30 |
2011-07-28 |
Gunther Hartmann |
Silencng and rig-i activation by dual function oligonucleotides
|
|
US8961967B2
(en)
|
2009-11-30 |
2015-02-24 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
JP5956982B2
(ja)
|
2010-05-27 |
2016-07-27 |
メルク・シャープ・エンド・ドーム・コーポレイション |
改善された特性を有する抗体の製造方法
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
WO2013064584A1
(en)
|
2011-10-31 |
2013-05-10 |
Riboxx Gmbh |
Double-stranded RNA for immunostimulation
|
|
US9283272B2
(en)
|
2012-03-30 |
2016-03-15 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Targeting intracellular target-binding determinants with intracellular antibodies
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
WO2014169049A1
(en)
|
2013-04-09 |
2014-10-16 |
Duke University |
2' fluoro-modified rnas as immunostimulators
|
|
US9775894B2
(en)
|
2013-07-09 |
2017-10-03 |
University Of Washington Through Its Center For Commercialization |
Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
|
|
AU2015204446A1
(en)
*
|
2014-01-13 |
2016-07-14 |
Valerion Therapeutics, Llc |
Internalizing moieties
|
|
WO2016033321A1
(en)
|
2014-08-28 |
2016-03-03 |
Yale University |
Multivalent fragments of antibody 3e10 and methods of use thereof
|
|
DE102015008536A1
(de)
|
2015-07-02 |
2017-01-05 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Diskontinuierliche Oligonukleotid-Liganden
|
|
WO2017079369A2
(en)
|
2015-11-03 |
2017-05-11 |
Glaxosmithkline Llc |
Novel antibodies
|
|
WO2017173427A1
(en)
|
2016-04-01 |
2017-10-05 |
Vycellix Inc |
Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
|
|
EP3471777A1
(en)
|
2016-06-15 |
2019-04-24 |
Yale University |
Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
|
|
KR20190057083A
(ko)
|
2016-10-06 |
2019-05-27 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
공정 불순물에 대한 결합이 감소된 항체
|
|
JP7062669B2
(ja)
|
2016-12-23 |
2022-05-06 |
ブリストル－マイヤーズ スクイブ カンパニー |
改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンｇ４の設計
|
|
US11382966B2
(en)
|
2017-03-24 |
2022-07-12 |
Rigontec Gmbh |
Method for designing RIG-I ligands
|
|
EP3655432A4
(en)
*
|
2017-07-17 |
2021-04-14 |
Nucleus Therapeutics Pty Ltd |
BINDING PROTEINS 1
|
|
WO2019143297A1
(en)
|
2018-01-17 |
2019-07-25 |
Nanyang Technological University |
Immunomodulatory small hairpin rna molecules
|
|
US20210137960A1
(en)
|
2018-02-01 |
2021-05-13 |
Yale University |
Compositions and methods for inhibition of nuclear-penetrating antibodies
|
|
WO2019152806A1
(en)
|
2018-02-01 |
2019-08-08 |
Yale University |
Compositions and methods for enhancing nuclear translocation
|
|
WO2019152884A1
(en)
|
2018-02-02 |
2019-08-08 |
University Of Washington |
Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling
|
|
JP7366057B2
(ja)
|
2018-04-19 |
2023-10-20 |
チェックメイト ファーマシューティカルズ， インコーポレイテッド |
合成ｒｉｇ－ｉ様受容体アゴニスト
|
|
EP3781687A4
(en)
|
2018-04-20 |
2022-02-09 |
Merck Sharp & Dohme Corp. |
NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
|
|
EP3810151B1
(en)
|
2018-06-20 |
2025-08-06 |
Yale University |
Rig-i agonists and treatments using same
|
|
CA3111186A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods for enhancing triplex and nuclease-based gene editing
|
|
EP3844287B1
(en)
|
2018-08-31 |
2024-05-22 |
Yale University |
Compositions and methods for enhancing donor oligonucleotide-based gene editing
|
|
EP3990635A1
(en)
|
2019-06-27 |
2022-05-04 |
Rigontec GmbH |
Design method for optimized rig-i ligands
|
|
EP4045656A1
(en)
|
2019-10-16 |
2022-08-24 |
SomaLogic Operating Co., Inc. |
Nucleic acid compounds that bind to retinoic acid-inducible gene i protein
|
|
AU2022302143A1
(en)
|
2021-07-02 |
2024-01-18 |
Yale University |
Compositions and methods for treating cancers
|